In which country is Cemiplimab available?

Cemiplimab (Cemiplimab) is a programmed death receptor-1 blocking antibody used to treat cutaneous squamous cell carcinoma, basal cell carcinoma and non-small cell lung cancer. It was first approved by the U.S. Food and Drug Administration (FDA) in September 2018, becoming the first FDA-approved drug for the treatment of advanced cutaneous squamous cell carcinoma (CSCC). The drug was subsequently approved for basal cell carcinoma and non-small cell lung cancer. Cimepilimab was also approved by the European Commission in June 2019. In October 2022, the European Medicines Agency (EMA) recommended granting marketing authorization for cimepilimab for the treatment of cervical cancer. Cimepilimab is not currently on the market in the country.